Uniqure N.V. (QURE) 7.37 $QURE Will Broadcom (AVGO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Uniqure N.V. (QURE) 7.37 $QURE

Will Broadcom (AVGO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:45AM CDT
Broadcom Limited (AVGO) is scheduled to report second-quarter fiscal 2016 results after the closing bell on Jun 2.
QURE: 7.37 (+0.10), CTRP: 43.09 (-0.58), COO: 182.61 (+0.14), AVGO: 163.51 (+1.53)

uniQure Announces Results for First Quarter 2016
GlobeNewswire - Tue May 31, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update.
QURE: 7.37 (+0.10)

uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:00AM CDT
- Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort -
QURE: 7.37 (+0.10)

uniQure to Present at Upcoming Investor Conferences in New York City
GlobeNewswire - Thu May 12, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in May and June, 2016.
QURE: 7.37 (+0.10)

uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
GlobeNewswire - Mon May 09, 3:24PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's Board of Directors. Mr. Kaye, who will also chair the Company's Audit Committee, is a seasoned financial executive with over 40 years of diversified experience. The Company also announced its intention to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members.
QURE: 7.37 (+0.10)

uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT
GlobeNewswire - Mon May 09, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new technologies to improve gene therapy as a therapeutic approach. The results were presented in poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting in Washington D.C. and highlight the progress uniQure has made in establishing optimized gene therapy delivery systems, re-administration protocols and vector technologies specifically in its key focus areas, liver/metabolism and CNS.
QURE: 7.37 (+0.10)

Biotech Company On The Rise
ACCESSWIRE - Tue May 03, 8:56AM CDT
New Website and Roadshow "May" Make for Huge Month for This Biotech
QURE: 7.37 (+0.10)

uniQure Appoints Paul Firuta as Chief Commercial Officer
GlobeNewswire - Tue May 03, 4:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr. Firuta, who held similar positions at NPS Pharmaceuticals, Inc. and ViroPharma, Inc., has 25 years of industry experience successfully commercializing products targeting rare diseases. As a key member of the leadership team, Mr. Firuta will oversee global commercial and portfolio planning, program management, and will work closely with the Company's cross-functional teams in building relationships with patient advocacy groups and key opinion leaders. He will report to Daniel Soland, Chief Executive Officer of uniQure, and be based out of the Company's Lexington, Massachusetts facility.
QURE: 7.37 (+0.10), ORPN: 1.62 (-0.10)

uniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
GlobeNewswire - Tue Apr 19, 1:16PM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting held in Washington D.C., May 4-7, 2016. Together with their collaborators, members of uniQure's research and development team will present data focused on progress in improving gene therapy delivery systems, re-administration protocols and vector technologies in two of uniQure's key focus areas, liver/metabolism and CNS.
QURE: 7.37 (+0.10)

CORRECTING and REPLACING -- uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 6:45AM CDT
In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected release follows:
QURE: 7.37 (+0.10)

uniQure Announces Results for Fourth Quarter and Financial Year 2015
GlobeNewswire - Mon Apr 04, 4:00AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a corporate overview on its pipeline programs and operations.
QURE: 7.37 (+0.10)

uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
GlobeNewswire - Tue Mar 22, 10:05AM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington's disease gene therapy program, AMT-130. Findings published in the current issue of the peer-reviewed journal Molecular Therapy-Nucleic Acids (www.nature.com/mtna/journal/v5/n3/index.html) provide preclinical proof of concept for uniQure's AMT-130 program and demonstrate the potential of a one-time administration of AAV5-delivered gene therapy into the central nervous system (CNS) to silence the Huntingtin gene (HTT). An inherited, mutated form of HTT causes Huntington's disease, a rare, fatal, neurodegenerative disorder that leads to severe physical and cognitive deterioration.
QURE: 7.37 (+0.10)

uniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
GlobeNewswire - Mon Mar 14, 5:00AM CDT
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The primary objective of the second cohort is to assess the safety of the systemic administration of a higher dose of uniQure's AMT-060 gene therapy in hemophilia B patients that present with a severe or moderately-severe disease phenotype. Secondary objectives of the trial include evaluation of Factor IX (FIX) activity levels as well as evaluation of annualized bleeding rates and recombinant FIX usage.
QURE: 7.37 (+0.10)

uniQure N.V. (QURE) Shows Strength: Stock Moves Up 5.3%
Zacks Equity Research - Zacks Investment Research - Mon Jan 11, 7:15AM CST
uniQure N.V. (QURE) shares rose over 5% in the last trading session.
QURE: 7.37 (+0.10), ANIK: 50.64 (+0.72)

Xenon Outlines Key Milestones for 2016
GlobeNewswire - Mon Jan 11, 7:00AM CST
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2016.
QURE: 7.37 (+0.10), XENE: 7.44 (-0.20)

uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Thu Jan 07, 5:00AM CST
--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector--
QURE: 7.37 (+0.10)

uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
GlobeNewswire - Wed Jan 06, 3:15PM CST
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
QURE: 7.37 (+0.10)

Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 11.49 (+0.37), CRIS: 1.74 (+0.06), QURE: 7.37 (+0.10), ARNA: 1.68 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 65

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 116

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
NCPDP Elevates J.W. Hill to President & COO Role

Updated Category News Views 46

Plotting the Course for NCPDP's Future Today's shakeup at the NCPDP has got the sector's ears perked. For those who don't speak in acronym soup all day—NCPDP stands for National Council for Prescription Drug Programs. They're the brains behind many crucial healthcare standards, improving information flow around meds, supplies, and services. Now, they're taking bold...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 170

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 68

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 45

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 100

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading

Top 5 Most Recently Viewed Articles

Patriot Rail Company Celebrated as a Top Workplace in 2025

Updated Category News Views 218

Patriot Rail Company Achieves Top Workplace Recognition Patriot Rail Company, a leading provider of short line and regional freight rail services, has proudly been recognized as one of the Top Workplaces for 2025 by USA TODAY. This prestigious award celebrates companies that prioritize their employees, ensuring a culture that is rich in support and engagement....

Continue Reading
Transform Your Holiday Spirit with Unique DIY Christmas Ornaments

Updated Category News Views 173

Discover the Joy of DIY Christmas Tree Ornaments As the holiday season approaches, families often seek special ways to celebrate and remember the joy of Christmas. One delightful approach is creating DIY Christmas tree ornaments. Handmade ornaments not only add warmth and creativity to your holiday decor, but they also give a personal touch that store-bought items simply...

Continue Reading
Understanding SkyWest Inc's Price to Earnings Ratio

Updated Category News Views 111

SkyWest Inc's Current Market Performance SkyWest Inc. (NASDAQ: SKYW) is currently seeing its share price at $102.58, marking a notable increase of 1.95% in the recent trading session. However, when looking at the broader picture, the stock has experienced a decline of 17.54% over the last month, while over the last year, the price has surprisingly surged by 20.94%. This...

Continue Reading
Luxury Brands Thrive Amid Positive Sales Trends

Updated Category News Views 366

Luxury Goods Market Experience Significant Upturn Today, shares in prestigious luxury goods companies witnessed a remarkable surge during European trading sessions. This surge follows a compelling end-of-year sales report from Richemont, renowned for its luxurious Cartier brand. The impressive sales performance has ignited optimism about a broader recovery within the...

Continue Reading
Actabl Welcomes Joseph Benjamin as New Technology Leader

Updated Category News Views 240

Actabl Welcomes Joseph Benjamin as New Technology Leader Actabl, a prominent software provider in the hospitality sector, has won a significant addition to its team with the appointment of Joseph Benjamin as the Chief Technology Officer (CTO). Joseph’s presence marks a pivotal moment for Actabl as it enhances its global technology strategies aimed at driving innovation...

Continue Reading